Pantoprazole

How to order Pantoprazole

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Pantoprazole on Prescriptsy

Pantoprazole is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Pantoprazole is a proton pump inhibitor (PPI) used to treat gastro-oesophageal reflux disease (GORD), peptic ulcers, Zollinger-Ellison syndrome, and as part of Helicobacter pylori eradication therapy.

It works by irreversibly blocking the proton pump (hydrogen-potassium ATPase) on the surface of gastric parietal cells, reducing stomach acid production by up to 97 percent.

Pantoprazole is available as 20 mg and 40 mg gastro-resistant tablets.

The 40 mg strength is a prescription-only medicine (POM) in the United Kingdom, while the 20 mg strength is available as a pharmacy (P) medicine for short-term heartburn relief.

Gastro-oesophageal reflux disease is one of the most common gastrointestinal conditions in the UK, affecting an estimated 10 to 20 percent of the adult population.

It occurs when stomach contents, including acid and pepsin, reflux into the oesophagus, causing symptoms such as heartburn (a burning sensation behind the breastbone), acid regurgitation, and difficulty swallowing.

Chronic untreated GORD can lead to oesophagitis (inflammation of the oesophageal lining), oesophageal stricture (narrowing), Barrett's oesophagus (a precancerous change in the lining), and, rarely, oesophageal adenocarcinoma.

Peptic ulcers, affecting the stomach or duodenum, are another major indication for PPI therapy, often caused by Helicobacter pylori infection or non-steroidal anti-inflammatory drug (NSAID) use.

This page provides a comprehensive clinical guide to pantoprazole, including how it works, dosage instructions, side effects, safety warnings, and how to obtain it in the United Kingdom.

Important safety information about pantoprazole

Before reading further, please note these essential safety points.

• Do not ignore alarm symptoms (difficulty swallowing, vomiting blood, unintentional weight loss, black tarry stools). Seek urgent medical attention as these may indicate serious underlying disease.
• Use the lowest effective dose for the shortest duration necessary, particularly for long-term treatment.
• Swallow gastro-resistant tablets whole. Do not crush, chew, or split them.
• Long-term PPI use may be associated with low magnesium, vitamin B12 deficiency, increased fracture risk, and gut infections. Your prescriber should review long-term therapy regularly.
• Tell your prescriber about all medicines you take, as pantoprazole may interact with certain drugs.

Understanding gastro-oesophageal reflux disease

GORD occurs when the anti-reflux barrier between the stomach and oesophagus fails to function adequately.

The lower oesophageal sphincter (LOS), a ring of muscle at the junction of the oesophagus and stomach, normally prevents the retrograde flow of gastric contents.

In GORD, the LOS may be weakened, relax inappropriately (transient lower oesophageal sphincter relaxations), or be disrupted by a hiatus hernia (where part of the stomach protrudes through the diaphragm into the chest).

When acidic gastric contents contact the oesophageal mucosa, which lacks the protective mucus layer of the stomach, inflammation and tissue damage can result.

Risk factors for GORD include obesity (increased intra-abdominal pressure), smoking (which relaxes the LOS and reduces salivary bicarbonate secretion), alcohol, pregnancy, hiatus hernia, certain foods (fatty foods, chocolate, coffee, citrus, tomatoes), and some medicines (calcium channel blockers, nitrates, theophylline, bisphosphonates).

Lying down shortly after eating, wearing tight clothing, and large meals can all provoke symptoms.

Typical GORD symptoms include heartburn (the most common symptom, described as a burning sensation rising from the epigastrium towards the throat), acid regurgitation (the sensation of acid in the mouth or throat), and waterbrash (sudden filling of the mouth with saliva).

Atypical symptoms include chronic cough, hoarseness, sore throat, chest pain (which can mimic cardiac pain), and dental erosion. Nocturnal symptoms are common and may disrupt sleep.

Understanding peptic ulcers

Peptic ulcers are breaks in the mucosal lining of the stomach (gastric ulcer) or duodenum (duodenal ulcer) that penetrate through the muscularis mucosae.

The two most common causes are Helicobacter pylori infection and NSAID use. H.

pylori is a gram-negative bacterium that colonises the gastric mucosa, causing chronic inflammation and disrupting the protective mucus layer.

NSAID use inhibits cyclooxygenase-1 (COX-1), reducing prostaglandin production, which impairs mucosal blood flow, mucus secretion, and bicarbonate production.

Other risk factors include smoking, alcohol, physiological stress (critical illness), and Zollinger-Ellison syndrome (a rare condition in which gastrin-secreting tumours cause massive acid hypersecretion).

Duodenal ulcers typically cause epigastric pain that occurs 2 to 3 hours after meals and is relieved by eating or antacids.

Gastric ulcers may cause pain that worsens with eating.

Complications include bleeding (haematemesis or melaena), perforation (sudden severe abdominal pain requiring emergency surgery), and pyloric stenosis (narrowing causing vomiting and weight loss).

How pantoprazole works

Gastric acid is produced by parietal cells in the gastric glands of the stomach body and fundus.

The proton pump (H+/K+ ATPase) is the final common pathway for acid secretion, regardless of whether the stimulus is histamine (acting on H2 receptors), acetylcholine (acting on muscarinic M3 receptors), or gastrin (acting on CCK-B receptors).

By irreversibly inhibiting the proton pump, pantoprazole blocks acid secretion at its source, providing more complete and sustained acid suppression than H2-receptor antagonists (such as ranitidine or famotidine), which block only the histamine pathway.

Pantoprazole is a prodrug. It is formulated as a gastro-resistant tablet to prevent degradation in the stomach.

After passing through the stomach, the enteric coating dissolves in the alkaline environment of the small intestine, allowing absorption.

The drug enters the bloodstream, is distributed to the parietal cells, and accumulates in the acidic secretory canaliculi, where it is protonated and converted to its active sulphenamide form.

This reactive metabolite forms covalent disulphide bonds with specific cysteine residues (primarily Cys813 and Cys822) on the alpha subunit of the H+/K+ ATPase, permanently inactivating the enzyme.

New acid secretion requires synthesis of new proton pump molecules, a process that takes 24 to 48 hours.

A single daily dose of pantoprazole can reduce 24-hour gastric acid output by approximately 80 to 97 percent, depending on the dose and duration of treatment.

Clinical evidence for pantoprazole

Pantoprazole has been extensively studied in randomised controlled trials for GORD, peptic ulcer disease, and H. pylori eradication.

In a meta-analysis of trials comparing PPIs for GORD, pantoprazole 40 mg daily was found to be comparable in efficacy to omeprazole 20 mg, lansoprazole 30 mg, and esomeprazole 40 mg for healing erosive oesophagitis over 4 to 8 weeks, with healing rates of approximately 80 to 90 percent.

For symptom relief in non-erosive reflux disease (NERD), pantoprazole 20 mg daily significantly reduced heartburn frequency and severity compared with placebo.

For duodenal ulcer healing, pantoprazole 40 mg daily achieves healing rates of approximately 90 percent at 2 weeks and 95 percent at 4 weeks.

For gastric ulcer, healing rates of approximately 85 to 90 percent are achieved at 4 to 8 weeks. In H.

pylori eradication, triple therapy regimens containing pantoprazole 40 mg twice daily plus two antibiotics achieve eradication rates of approximately 80 to 90 percent, comparable to other PPI-based regimens.

NICE guideline CG184 (Gastro-oesophageal reflux disease and dyspepsia in adults) recommends a full-dose PPI for 4 to 8 weeks as initial treatment for GORD with oesophagitis, followed by stepping down to the lowest effective dose for maintenance.

For uninvestigated dyspepsia in patients under 55 without alarm features, a test-and-treat strategy for H. pylori or a trial of PPI therapy is recommended.

Pantoprazole compared with other PPIs

Five PPIs are available in the UK: omeprazole, lansoprazole, pantoprazole, rabeprazole, and esomeprazole. All are broadly similar in efficacy.

Omeprazole and lansoprazole are the most widely prescribed and are available as inexpensive generics.

Esomeprazole (the S-enantiomer of omeprazole) may offer marginally higher healing rates for severe erosive oesophagitis but the clinical difference is small.

Pantoprazole has the advantage of fewer CYP2C19-mediated drug interactions compared with omeprazole and esomeprazole, making it a preferred choice for patients taking multiple medicines, particularly clopidogrel (though the clinical significance of the omeprazole-clopidogrel interaction remains debated).

Rabeprazole is metabolised mainly by a non-enzymatic pathway, also resulting in fewer interactions.

H2-receptor antagonists (famotidine, ranitidine) provide less potent acid suppression than PPIs and are generally used for mild, intermittent symptoms or as step-down therapy after PPI healing.

Antacids (calcium carbonate, magnesium hydroxide, aluminium hydroxide) and alginates (sodium alginate, as in Gaviscon) provide rapid but short-lived symptomatic relief and are often used for occasional heartburn or as adjuncts to PPI therapy.

Dosage and administration

Take pantoprazole 30 to 60 minutes before a meal, usually before breakfast. Swallow the gastro-resistant tablet whole with water. Do not crush, chew, or break the tablet.

For twice-daily dosing (H. pylori eradication, Zollinger-Ellison), take the second dose before the evening meal.

For GORD, an initial course of 4 to 8 weeks at 20 to 40 mg daily is typical, followed by review and step-down to the lowest effective dose.

For peptic ulcers, treatment duration varies (2 to 8 weeks depending on ulcer type and healing response). For Zollinger-Ellison syndrome, treatment is long-term and specialist-directed.

NICE recommends that all patients on long-term PPI therapy should have their treatment reviewed at least annually, with an attempt to step down the dose or switch to on-demand use where appropriate.

Side effects of pantoprazole

Common side effects

Headache, diarrhoea, nausea, abdominal pain, constipation, flatulence, and dizziness are the most commonly reported side effects. They are usually mild, self-limiting, and similar across all PPIs.

Long-term risks

Hypomagnesaemia (low magnesium) can develop with prolonged use and may cause fatigue, muscle cramps, tremor, seizures, or cardiac arrhythmias.

The MHRA advises monitoring magnesium levels in patients expected to take PPIs long term. Vitamin B12 deficiency may result from impaired acid-dependent release of B12 from food proteins.

Iron deficiency may occur through a similar mechanism.

Reduced calcium absorption may contribute to an increased risk of osteoporotic fractures (hip, wrist, spine), particularly in elderly patients and those on high doses.

Clostridioides difficile infection risk is elevated because reduced gastric acidity allows bacterial overgrowth. Community-acquired pneumonia risk may be slightly increased.

Rare serious effects

Acute interstitial nephritis is a rare idiosyncratic reaction presenting with fever, rash, and declining renal function. Subacute cutaneous lupus erythematosus (SCLE) has been reported rarely.

Fundic gland polyps may develop with long-term use but are benign and rarely symptomatic. Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) are extremely rare.

When to seek medical advice

Stop pantoprazole and seek urgent medical attention if you develop a severe allergic reaction (swelling of the face, lips, tongue, or throat; difficulty breathing), jaundice, severe diarrhoea (particularly if bloody or associated with fever), or a widespread rash in sun-exposed areas.

Call 999 in an emergency. Contact your GP or NHS 111 for persistent abdominal pain, unexplained weight loss, difficulty swallowing, or black tarry stools.

Report suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Alarm symptoms

Unintentional weight loss, progressive dysphagia, persistent vomiting, haematemesis, melaena, iron-deficiency anaemia, an epigastric mass, or new dyspepsia in patients aged 55 or over are alarm features that require urgent investigation (usually endoscopy) to exclude gastric or oesophageal malignancy.

PPI therapy may mask symptoms and delay diagnosis. Do not start pantoprazole without appropriate assessment if alarm features are present.

Drug interactions

Pantoprazole should not be used with atazanavir or nelfinavir, as reduced gastric acidity significantly decreases their absorption and efficacy.

It may reduce the absorption of ketoconazole, itraconazole, posaconazole, and erlotinib.

High-dose methotrexate levels may be increased by concurrent PPI use; temporary discontinuation of the PPI may be advisable.

Monitor INR in patients on warfarin when starting or stopping pantoprazole, although clinically significant interactions are uncommon.

Pantoprazole does not significantly inhibit CYP2C19 at therapeutic doses and has a lower interaction potential than omeprazole.

Rebound acid hypersecretion

Stopping a PPI abruptly after prolonged use (more than 8 weeks) may cause rebound acid hypersecretion, with temporary worsening of symptoms. This can create a cycle of dependence.

Taper the dose gradually over 2 to 4 weeks, or switch to on-demand use, when discontinuing long-term therapy.

Lifestyle measures for GORD

Alongside pantoprazole treatment, lifestyle modifications can help manage GORD symptoms. Maintain a healthy weight, as obesity increases intra-abdominal pressure and promotes reflux.

Elevate the head of the bed by 10 to 20 cm if nocturnal symptoms are troublesome. Avoid eating large meals within 3 hours of bedtime.

Reduce intake of known triggers (fatty foods, chocolate, coffee, alcohol, citrus, tomatoes, spicy foods). Stop smoking, as tobacco relaxes the lower oesophageal sphincter and reduces salivary bicarbonate.

Avoid tight-fitting clothing around the waist. Chewing sugar-free gum after meals increases saliva flow, which helps neutralise refluxed acid.

How to get pantoprazole in the UK

Pantoprazole 40 mg is available on NHS prescription from your GP or an authorised online prescriber registered with the General Pharmaceutical Council (GPhC).

The standard NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Pantoprazole 20 mg is available from pharmacies as a pharmacy (P) medicine without prescription, for short-term relief of reflux symptoms in adults aged 18 and over (usually a maximum of 4 weeks' supply at a time).

Consult your pharmacist for advice.

Sources

• Pantoprazole 40 mg gastro-resistant tablets, Summary of Product Characteristics (EMC)
• Pantoprazole, British National Formulary (BNF)
• NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults
• NICE NG183: Gastro-oesophageal reflux disease in children and young people
• Heartburn and acid reflux, NHS
• MHRA Yellow Card Scheme